Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 129% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 8/9 — financially strong with improving fundamentals
- Strong ROE of 23.0% with 27.2% net margin
- Revenue growing at 10% annually
ResMed Inc. (RMD) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $32.9 billion . Key value metrics: P/E ratio 22.7, P/B ratio 5.21, Piotroski F-Score 8 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
ResMed Inc. — Fundamental Analysis Summary
ResMed Inc. (RMD) is currently trading 129% above its Graham Number of $98.60, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 22.7x.
On financial health, RMD shows a strong Piotroski F-Score of 8/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 23.0% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.11.
StockPik's composite Value Score for RMD is 89/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
RMD reports a high gross margin of 60.3% (sector average: 33.5%) and a strong operating margin of 33.4%.
RMD shows revenue growing at 10% year-over-year, with earnings growing at 37%.
RMD pays a modest dividend yield of 1.0%.